Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials.
Radhoe SP, Boersma E, Bertrand M, Remme W, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML, Brugts JJ. Radhoe SP, et al. Among authors: brugts jj. Cardiovasc Drugs Ther. 2024 Feb;38(1):131-139. doi: 10.1007/s10557-022-07384-2. Epub 2022 Oct 4. Cardiovasc Drugs Ther. 2024. PMID: 36194352 Free PMC article.
Intensity of statin therapy in relation to myocardial ischemia, troponin T release, and clinical cardiac outcome in patients undergoing major vascular surgery.
Feringa HH, Schouten O, Karagiannis SE, Brugts J, Elhendy A, Boersma E, Vidakovic R, van Sambeek MR, Noordzij PG, Bax JJ, Poldermans D. Feringa HH, et al. Among authors: brugts j. J Am Coll Cardiol. 2007 Oct 23;50(17):1649-56. doi: 10.1016/j.jacc.2007.06.046. J Am Coll Cardiol. 2007. PMID: 17950146 Free article. Clinical Trial.
The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
Brugts JJ, Boersma E, Chonchol M, Deckers JW, Bertrand M, Remme WJ, Ferrari R, Fox K, Simoons ML; EUROPA Investigators. Brugts JJ, et al. J Am Coll Cardiol. 2007 Nov 27;50(22):2148-55. doi: 10.1016/j.jacc.2007.08.029. Epub 2007 Nov 13. J Am Coll Cardiol. 2007. PMID: 18036453 Free article. Clinical Trial.
The microcirculation in health and critical disease.
den Uil CA, Klijn E, Lagrand WK, Brugts JJ, Ince C, Spronk PE, Simoons ML. den Uil CA, et al. Among authors: brugts jj. Prog Cardiovasc Dis. 2008 Sep-Oct;51(2):161-70. doi: 10.1016/j.pcad.2008.07.002. Prog Cardiovasc Dis. 2008. PMID: 18774014 Review.
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
Brugts JJ, de Maat MP, Boersma E, Witteman JC, van Duijn C, Uitterlinden AG, Bertrand M, Remme W, Fox K, Ferrari R, Danser AH, Simoons ML; EUROPA-PERGENE investigators. Brugts JJ, et al. Cardiovasc Drugs Ther. 2009 Apr;23(2):171-81. doi: 10.1007/s10557-008-6156-1. Epub 2008 Dec 10. Cardiovasc Drugs Ther. 2009. PMID: 19082699
Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial).
Brugts JJ, Mercado N, Hu S, Guarneri M, Price M, Schatz R, Teirstein P, Wijns W, Serruys PW, O'Neill WW, Boersma E. Brugts JJ, et al. Am J Cardiol. 2009 Apr 1;103(7):917-22. doi: 10.1016/j.amjcard.2008.12.017. Epub 2009 Feb 7. Am J Cardiol. 2009. PMID: 19327416 Clinical Trial.
219 results